Table 1.
Pathology Summary
| Formulation and Dose | Muscle Fiber Necrosis | Mixed-Cell Inflammation | Degenerate Neutrophils | Mixed-Cell Inflammation | Degenerate Neutrophils |
|---|---|---|---|---|---|
| MC3 | |||||
| 0.01 mg | 2.3 | 2.4 | 1.7 | 2 | 0 |
| 0.1 mg | 2.3 | 2.7 | 3.3 | 2 | 1 |
| Lipid H | |||||
| 0.01 mg | 1 | 1.8 | 1 | 0 | 0 |
| 0.1 mg | 1.3 | 2.9 | 2.3 | 1.3 | 0 |
| Lipid M | |||||
| 0.01 mg | 2 | 2 | 1.3 | 1.7 | 0 |
| 0.1 mg | 1.7 | 2.7 | 2 | 2 | 0 |
| Lipid P | |||||
| 0.01 mg | 2.3 | 2.2 | 1.7 | 1.3 | 0 |
| 0.1 mg | 2.3 | 2.8 | 2.3 | 2.3 | 0.7 |
| Lipid Q | |||||
| 0.01 mg | 2.3 | 2.2 | 2 | 0.7 | 0 |
| 0.1 mg | 2 | 2.9 | 3 | 2.5 | 1 |
| Lipid N | |||||
| 0.01 mg | 0.7 | 1.4 | 2 | 0 | 0 |
| 0.1 mg | 1.3 | 2 | 2.3 | 0 | 0 |
Rats (n = 3 per group) were injected IM with 0.01 or 0.1 mg modified mRNA encoding prM-E from the Zika virus formulated in LNPs containing MC3 or lipid H. Average histopathology scores on a 0–4 scale were recorded for events occurring in the muscle and skin.